CHIMERIC THERAPEUTICS
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.
CHIMERIC THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2020-01-01
Address:
Carlton South, Victoria, Australia
Country:
Australia
Website Url:
http://www.chimerictherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+61 3 98245254
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.chimerictherapeutics.com Semrush global rank: 5.09 M Semrush visits lastest month: 1.61 K
- Host name: 3.4.180.107.host.secureserver.net
- IP address: 107.180.4.3
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Chimeric Therapeutics" on Search Engine
Chimeric Therapeutics - Crunchbase Company Profile & Funding
Company Type For Profit. Contact Email [email protected]. Phone Number +61 3 98245254. Chimeric Therapeutics is a company developing ground-breaking …See details»
Chimeric Therapeutics | LinkedIn
Chimeric Therapeutics is the ASX leader in cell therapy. As the only clinical stage, cell therapy biotechnology company in Australia, our focus is on discovering, developing and …See details»
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE …
SYDNEY, Oct. 31, 2023 /PRNewswire/ -- Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. …See details»
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE …
Oct 31, 2023 Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug …See details»
Chimeric enters strategic manufacturing partnership with
Apr 12, 2022 MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an …See details»
Chimeric Therapeutics Takes Cell Therapy From Biotech Dream …
Dec 27, 2021 8 Follower s. Summary. Chimeric Therapeutics focuses on curative cell therapy solutions — proactive rather than reactive. Listed on Australian Securities …See details»
Chimeric Therapeutics Limited investor hub | ASX:CHM
May 2, 2024 Welcome to the Chimeric Therapeutics Limited investor hub. Be the first to get notified about Chimeric Therapeutics Limited news, updates, and announcements. …See details»
Chimeric Therapeutics Company Profile - Craft
May 9, 2024 Overview. Chimeric Therapeutics is a clinical-stage cell therapy company. It offers NK and T cell-derived allogeneic therapies, clinical trials, and other services for …See details»
Chimeric Therapeutics Company Profile 2024: Stock Performance ...
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in …See details»
Chimeric Therapeutics To Attend BIO International Convention
Jun 5, 2023 SYDNEY, Australia and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Chimeric Therapeutics (ASX: CHM) (“Chimeric Therapeutics”, “Chimeric” or the …See details»
Chimeric Therapeutics and OncoBay Clinical Form Partnership to …
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce that it has entered a strategic partnership with …See details»
Chimeric Therapeutics - BIO International Convention | BIO
Jun 5, 2023 Chimeric Therapeutics is a clinical stage cell therapy company with encouraging early clinical data in Glioblastoma with CHM 1101 and in HR-MDS/ AML …See details»
Chimeric Partners with Be The Match BioTherapies to Advance …
Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with …See details»
Chimeric Therapeutics - Contacts, Employees, Board Members, …
Organization. Chimeric Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 3. …See details»
Fighting lymphoma: Treatment options include alternatives to ...
3 days ago There were roughly a half-million new cases of non-Hodgkin lymphoma and 82,409 new cases of Hodgkin lymphoma in 2022, making them the 10 th and 26 th most …See details»
Facts and Hopes on Chimeric Cytokine Agents for Cancer …
2 days ago Abstract. Cytokines are key mediators of immune responses that can modulate the antitumor activity of immune cells. Cytokines have been explored as a promising …See details»
Annual Report - Chimeric Therapeutics
Jun 30, 2021 Chimeric Therapeutics is led by a team of cell therapy pioneers and experts who have workedn o the development of over 25 cell therapies, including 4/ 5 of the …See details»
Chimeric Therapeutics jobs - Indeed
48 Chimeric Therapeutics jobs available on Indeed.com. Apply to Scientist, Development Director, Executive Assistant and more!See details»
Chimeric enters partnership with WuXi Advanced Therapies
Apr 14, 2022 Chimeric Therapeutics (ASX:CHM, “Chimeric”) a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has …See details»
British Journal of Haematology | Wiley Online Library
5 days ago Atrial arrhythmias were nearly fourfold more likely to be reported after CAR-T therapy compared to all other cancer patients in the FAERS (adjusted ROR = 3.76 [95% …See details»